Pharmaceutical M&A got a late-year shot in the arm, with nearly $10 billion in deals involving major industry players like AstraZeneca and Bayer as 2013 came to a close. A bevy of Am Law 100 firms led by Covington, Kirkland, Sullivan & Cromwell, Skadden, and Weil have grabbed lead roles on the transactions.
This article has been archived, and is no longer available on this website.
LexisNexis® is now the exclusive third party online distributor of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® customers will be able to access and use ALM's content by subscribing to the LexisNexis® services via lexis.com® and Nexis®. This includes content from The National Law Journal®, The American Lawyer®, Law Technology News®, The New York Law Journal® and Corporate Counsel®, as well as ALM's other newspapers, directories, legal treatises, published and unpublished court opinions, and other sources of legal information.
ALM's content plays a significant role in your work and research, and now through this alliance LexisNexis® will bring you access to an even more comprehensive collection of legal content.